Navigation Links
USC researchers develop new drug to target tumor cells and blood vessels
Date:4/20/2009

Researchers at the University of Southern California have identified a new drug compound that appears to target tumor cells and surrounding blood vessels without the negative side effects typically associated with Cox-2 inhibitors.

The compound 2.5-dimethyl-celecoxib (DMC) appears to have a strong anti-tumor effect while also attacking the vasculature that provides the blood supply necessary for tumor growth, according to data presented at the AACR 100th Annual Meeting 2009. The findings were presented at a 1 p.m. news conference on Sunday, April 19.

"If left behind, the blood vessels within the tumor will help the tumor cells to survive and re-grow," says Florence M. Hofman, Ph.D., professor of pathology at the Keck School of Medicine of USC. "We believe that DMC will be particularly useful for treating brain tumors such as gliomas, which are highly vascular. It also appears very promising for long-term treatment because it does not have the negative cardiovascular effects associated with Cox-2 inhibitors."

Cox-2 inhibitors are most commonly used as anti-inflammatory drugs and have been shown to be effective in treating certain kinds of cancer. However, long-term use has also been associated with increased risk of heart attack and stroke, Hofman explains. DMC, however, retains anti-tumor activity without inhibition of Cox-2 and the associated increased risk of cardiovascular complications.

Hofman and colleagues from the Keck School of Medicine tested the effectiveness of the DMC compound by isolating endothelial cellsthe cells that line the interior surface of blood vesselsfrom human nonmalignant brain and glioma tissues and treating them with DMC.

They found that the drug was cytotoxic to tumor-associated endothelial cells and suppressed cell proliferation and migration without apparent toxic effects to normal tissues. Drug therapy in animal studies also showed smaller tumors and fewer blood vessels in the tumors, with a 35 to 40 percent reduction in blood vessel density.

"While our research focused on brain tumors, we believe this drug may work in a number of different tumors that are dependent on blood vessels," Hofman says. "Further research will help us to understand its full potential."


'/>"/>

Contact: Meghan Lewit
lewit@usc.edu
323-442-3941
University of Southern California
Source:Eurekalert

Related medicine news :

1. Stanford researchers find culprit in aging muscles that heal poorly
2. UCLA researchers identify markers that may predict diabetes in still-healthy people
3. Mayo Clinic researchers discover new diagnostic test for detecting infection in prosthetic joints
4. Bipolar disorder relapses halved by Melbourne researchers
5. Cell that triggers symptoms in allergy attacks can also limit damage, Stanford researchers find
6. High and mighty: first common height gene identified by researchers behind obesity gene finding
7. Researchers estimate about 9 percent of US children age 8 to 15 meet criteria for having ADHD
8. Majority of 2.4 Million U.S. Children With ADHD Not Diagnosed or Consistently Treated, According to New Gold Standard Study by Cincinnati Childrens Researchers
9. Researchers develop long-lasting growth hormone
10. Jefferson immunology researchers halt lethal rabies infection in brain
11. Purdue researchers develop technology to detect cancer by scanning surface veins
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... 2017 , ... Information about the technology: , Otomagnetics has ... prevention of a major side effect of chemotherapy in children. Cisplatin and carboplatin ... cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. Hearing ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in ... 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced ... 2017. , The annual award competition recognizes editorial and design excellence across a range ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the Health ... Miles by Moonlight to raise money for the American Heart Association Heart Walk. Teams ... Teams will work together to keep their treadmills moving for 5 hours. Treadmills will ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... first interactive health literacy software tool, and the Cancer Patient Education Network (CPEN), ... patient education, today announce a new strategic alliance. , As CPEN’s strategic ...
(Date:10/12/2017)... Miramar, FL (PRWEB) , ... October 12, 2017 ... ... is presenting the latest in wound care advancements to physician colleagues, skilled nursing ... lecture is titled, "Navigating the Treacherous Waters of Wound Care." , "At many ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... 12, 2017   Divoti USA will engrave ... the standard of the latest FDA requirements, which stipulates new criteria ... Anyone in need of Medical ID jewelry such as Medical ID ... are engraved in terms of the new FDA requirements . ... Divoti offers this dark mark ...
(Date:10/11/2017)... 2017  True Health, a leader in integrated ... during National Breast Cancer Awareness month to educate ... Research recently published ... more than 10 million American women are at ... or BRCA2 and have not had testing. These mutations ...
(Date:10/7/2017)... Oct. 6, 2017   Provista, a proven ... $100 billion in purchasing power, today announced a new ... The Newsroom is the online home for ... infographics, expert bios, news releases, slideshows and events. ... a wealth of resources at their fingertips, viewers can ...
Breaking Medicine Technology: